Literature DB >> 24533266

The proteasome of malaria parasites: A multi-stage drug target for chemotherapeutic intervention?

Makoah Nigel Aminake1, Hans-Dieter Arndt2, Gabriele Pradel1.   

Abstract

The ubiquitin/proteasome system serves as a regulated protein degradation pathway in eukaryotes, and is involved in many cellular processes featuring high protein turnover rates, such as cell cycle control, stress response and signal transduction. In malaria parasites, protein quality control is potentially important because of the high replication rate and the rapid transformations of the parasite during life cycle progression. The proteasome is the core of the degradation pathway, and is a major proteolytic complex responsible for the degradation and recycling of non-functional ubiquitinated proteins. Annotation of the genome for Plasmodium falciparum, the causative agent of malaria tropica, revealed proteins with similarity to human 26S proteasome subunits. In addition, a bacterial ClpQ/hslV threonine peptidase-like protein was identified. In recent years several independent studies indicated an essential function of the parasite proteasome for the liver, blood and transmission stages. In this review, we compile evidence for protein recycling in Plasmodium parasites and discuss the role of the 26S proteasome as a prospective multi-stage target for antimalarial drug discovery programs.

Entities:  

Keywords:  Inhibitor; Plasmodium falciparum; Proteasome; Ubiquitin

Year:  2012        PMID: 24533266      PMCID: PMC3862440          DOI: 10.1016/j.ijpddr.2011.12.001

Source DB:  PubMed          Journal:  Int J Parasitol Drugs Drug Resist        ISSN: 2211-3207            Impact factor:   4.077


  79 in total

1.  Unraveling the ubiquitome of the human malaria parasite.

Authors:  Nadia Ponts; Anita Saraf; Duk-Won D Chung; Alona Harris; Jacques Prudhomme; Michael P Washburn; Laurence Florens; Karine G Le Roch
Journal:  J Biol Chem       Date:  2011-09-19       Impact factor: 5.157

Review 2.  Protein degradation: recognition of ubiquitinylated substrates.

Authors:  Rasmus Hartmann-Petersen; Colin Gordon
Journal:  Curr Biol       Date:  2004-09-21       Impact factor: 10.834

Review 3.  Ubiquitin: same molecule, different degradation pathways.

Authors:  Michael J Clague; Sylvie Urbé
Journal:  Cell       Date:  2010-11-24       Impact factor: 41.582

Review 4.  Targeting the Plasmodium ubiquitin/proteasome system with anti-malarial compounds: promises for the future.

Authors:  Duk-Won Doug Chung; Karine G Le Roch
Journal:  Infect Disord Drug Targets       Date:  2010-06

5.  ATP-dependent degradation of SulA, a cell division inhibitor, by the HslVU protease in Escherichia coli.

Authors:  I S Seong; J Y Oh; S J Yoo; J H Seol; C H Chung
Journal:  FEBS Lett       Date:  1999-07-30       Impact factor: 4.124

Review 6.  Proteasome inhibitors: Dozens of molecules and still counting.

Authors:  Geoffroy de Bettignies; Olivier Coux
Journal:  Biochimie       Date:  2010-07-06       Impact factor: 4.079

7.  The proteasome inhibitor MLN-273 blocks exoerythrocytic and erythrocytic development of Plasmodium parasites.

Authors:  C Lindenthal; N Weich; Y S Chia; V Heussler; M Q Klinkert
Journal:  Parasitology       Date:  2005-07       Impact factor: 3.234

8.  Thiostrepton and derivatives exhibit antimalarial and gametocytocidal activity by dually targeting parasite proteasome and apicoplast.

Authors:  Makoah N Aminake; Sebastian Schoof; Ludmilla Sologub; Monika Leubner; Marc Kirschner; Hans-Dieter Arndt; Gabriele Pradel
Journal:  Antimicrob Agents Chemother       Date:  2011-01-18       Impact factor: 5.191

Review 9.  Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy.

Authors:  Robert C Kane; Peter F Bross; Ann T Farrell; Richard Pazdur
Journal:  Oncologist       Date:  2003

10.  Characterization of a UBC13 kinase in Plasmodium falciparum.

Authors:  Nisha Philip; Timothy A Haystead
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-23       Impact factor: 11.205

View more
  32 in total

1.  Plasmodium chaperonin TRiC/CCT identified as a target of the antihistamine clemastine using parallel chemoproteomic strategy.

Authors:  Kuan-Yi Lu; Baiyi Quan; Kayla Sylvester; Tamanna Srivastava; Michael C Fitzgerald; Emily R Derbyshire
Journal:  Proc Natl Acad Sci U S A       Date:  2020-03-03       Impact factor: 11.205

Review 2.  Protein Degradation Systems as Antimalarial Therapeutic Targets.

Authors:  Caroline L Ng; David A Fidock; Matthew Bogyo
Journal:  Trends Parasitol       Date:  2017-07-05

3.  In vitro antimalarial activity of novel semisynthetic nocathiacin I antibiotics.

Authors:  Indu Sharma; Margery Sullivan; Thomas F McCutchan
Journal:  Antimicrob Agents Chemother       Date:  2015-03-16       Impact factor: 5.191

4.  Susceptibilities of Ugandan Plasmodium falciparum Isolates to Proteasome Inhibitors.

Authors:  Shreeya Garg; Oriana Kreutzfeld; Sevil Chelebieva; Patrick K Tumwebaze; Oswald Byaruhanga; Martin Okitwi; Stephen Orena; Thomas Katairo; Samuel L Nsobya; Melissa D Conrad; Ozkan Aydemir; Jennifer Legac; Alexandra E Gould; Brett R Bayles; Jeffrey A Bailey; Maelle Duffey; Gang Lin; Laura A Kirkman; Roland A Cooper; Philip J Rosenthal
Journal:  Antimicrob Agents Chemother       Date:  2022-09-12       Impact factor: 5.938

5.  Broad-spectrum antimalarial activity of peptido sulfonyl fluorides, a new class of proteasome inhibitors.

Authors:  Serena Tschan; Arwin J Brouwer; Paul R Werkhoven; Anika M Jonker; Lena Wagner; Sarah Knittel; Makoah Nigel Aminake; Gabriele Pradel; Fanny Joanny; Rob M J Liskamp; Benjamin Mordmüller
Journal:  Antimicrob Agents Chemother       Date:  2013-05-20       Impact factor: 5.191

6.  Targeting the cell stress response of Plasmodium falciparum to overcome artemisinin resistance.

Authors:  Con Dogovski; Stanley C Xie; Gaetan Burgio; Jess Bridgford; Sachel Mok; James M McCaw; Kesinee Chotivanich; Shannon Kenny; Nina Gnädig; Judith Straimer; Zbynek Bozdech; David A Fidock; Julie A Simpson; Arjen M Dondorp; Simon Foote; Nectarios Klonis; Leann Tilley
Journal:  PLoS Biol       Date:  2015-04-22       Impact factor: 8.029

7.  Prediction of Human-Plasmodium vivax Protein Associations From Heterogeneous Network Structures Based on Machine-Learning Approach.

Authors:  Apichat Suratanee; Teerapong Buaboocha; Kitiporn Plaimas
Journal:  Bioinform Biol Insights       Date:  2021-06-16

Review 8.  Targeting SUMOylation in Plasmodium as a Potential Target for Malaria Therapy.

Authors:  Daffiny Sumam de Oliveira; Thales Kronenberger; Giuseppe Palmisano; Carsten Wrenger; Edmarcia Elisa de Souza
Journal:  Front Cell Infect Microbiol       Date:  2021-06-10       Impact factor: 5.293

9.  Treatment of Plasmodium chabaudi Parasites with Curcumin in Combination with Antimalarial Drugs: Drug Interactions and Implications on the Ubiquitin/Proteasome System.

Authors:  Zoraima Neto; Marta Machado; Ana Lindeza; Virgílio do Rosário; Marcos L Gazarini; Dinora Lopes
Journal:  J Parasitol Res       Date:  2013-04-03

10.  Changes in the transcriptome of the malaria parasite Plasmodium falciparum during the initial phase of transmission from the human to the mosquito.

Authors:  Che Julius Ngwa; Matthias Scheuermayer; Gunnar Rudolf Mair; Selina Kern; Thomas Brügl; Christine Clara Wirth; Makoah Nigel Aminake; Jochen Wiesner; Rainer Fischer; Andreas Vilcinskas; Gabriele Pradel
Journal:  BMC Genomics       Date:  2013-04-15       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.